Nippon Shinyaku Co., Ltd. (4516.T) JPX

5,311.00

+16(+0.30%)

Updated at April 03 03:30PM

Currency In JPY

Key Executives

Name	Title	Year Born
Hayato Wada	Corporate Officer & Department Manager of Kansai Business Office	N/A
Kazuyuki Iwata	Director of Sales and Marketing & Director	1966
Manabu Beppu	Corporate Officer and Head of R & D Planning and Administration Dept.	N/A
Masaya Toda	Head of Licensing & Alliance Division and Corporate Officer	N/A
Hideyuki Fujii	Accounting & Finance Department Manager	N/A
Hitoshi Ishizawa	GM of Functional Food Division & Director	1961
Takanori Edamitsu	Head of Business Management & Sustainability and Director	1963
Takashi Takaya	GM of Personnel, General Affairs, Risk Mgmt, Compliance & Digital Trans and Director	1960
Toru Nakai	President & Director	1971
Yoko Nakanishi	Corporate Officer & Department Manager of Human Resources Dept.	N/A

Name

Title

Pay

Year Born

Hayato Wada

Corporate Officer & Department Manager of Kansai Business Office

N/A

Kazuyuki Iwata

Director of Sales and Marketing & Director

1966

Manabu Beppu

Corporate Officer and Head of R & D Planning and Administration Dept.

N/A

Masaya Toda

Head of Licensing & Alliance Division and Corporate Officer

N/A

Hideyuki Fujii

Accounting & Finance Department Manager

N/A

Hitoshi Ishizawa

GM of Functional Food Division & Director

1961

Takanori Edamitsu

Head of Business Management & Sustainability and Director

1963

Takashi Takaya

GM of Personnel, General Affairs, Risk Mgmt, Compliance & Digital Trans and Director

1960

Toru Nakai

President & Director

1971

Yoko Nakanishi

Corporate Officer & Department Manager of Human Resources Dept.

N/A

Description

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.